WHIZ PARTNERS
Invests in companies in Japan, the U.S., Europe,and Asia, focusing on life science, bio-technology, and information technology fields Establishes and manages partnership funds Provides consulting services on IPO and other corporate management aspects Intermediates M & A, MBO, and corporate rehabilitation deals Provides accounting and screening services for investment businesses
WHIZ PARTNERS
Industry:
Biotechnology Life Science Venture Capital
Founded:
2010-09-01
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta SPF Google Analytics Google Tag Manager WordPress Google Universal Analytics Apache Wordpress Plugins Global Site Tag Euro
Similar Organizations
BioAdvance
BioAdvance is a Pennsylvania-based venture capital firm that provides funding to life sciences startups.
Quaker BioVentures
Quaker BioVentures is a venture capital firm investing in life science companies. The firm leads investments across the spectrum of the
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-12-12 | Caresyntax | Whiz Partners investment in Series B - Caresyntax | 45.6 M USD |
| 2018-09-17 | WHILL | Whiz Partners investment in Series C - WHILL | 5 B JPY |
| 2017-10-05 | Inspec | Whiz Partners investment in Post-IPO Equity - Inspec | 5.41 M JPY |
| 2017-10-05 | CLARRO Inc. | Whiz Partners investment in Post-IPO Debt - CLARRO Inc. | 500 M JPY |
| 2017-04-20 | Tocagen | Whiz Partners investment in Post-IPO Equity - Tocagen | 72.5 M USD |
| 2016-12-01 | Immuno-Biological Laboratories | Whiz Partners investment in Post-IPO Debt - Immuno-Biological Laboratories | 1.39 B JPY |
| 2016-11-21 | ALBERT | Whiz Partners investment in Post-IPO Debt - ALBERT | 2.41 B JPY |
| 2016-11-14 | FRONTEO | Whiz Partners investment in Post-IPO Debt - FRONTEO | 2.5 B JPY |
| 2016-06-14 | Medrx | Whiz Partners investment in Post-IPO Debt - Medrx | 651.66 M JPY |
| 2016-04-06 | SymBio Pharmaceuticals | Whiz Partners investment in Post-IPO Debt - SymBio Pharmaceuticals | 3.01 B JPY |